Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Gain Therapeutics cleared to start study of GT-02287 in Australia

Broad Application of Gain Therapeutics' Structurally Targeted

Gain Therapeutics' Small Molecule Approach for CNS Diseases

Matthias Alder - CEO at Gain Therapeutics

MPS-Visita a GAIN Therapeutics

Gain Therapeutics (@GainThera) / X

Gain's clinical Parkinson's drug restores motor function in mice

Gain Therapeutics: Focused on developing new medicines for protein

Gain Therapeutics' Small Molecule Approach for CNS Diseases

Gain Therapeutics and UMSOM Partner to Investigate Small Molecule

Gain Therapeutics R&D Day: Professor Xavier Barril